Use a DOAC for Secondary Stroke Prevention in Cardiac Amyloidosis
For a patient with cardiac amyloidosis who suffered an acute ischemic stroke, you should use a direct oral anticoagulant (DOAC) rather than dual antiplatelet therapy (DAPT) for secondary prevention. This recommendation is based on the clear guideline mandate that cardiac amyloidosis requires anticoagulation regardless of other risk factors.
The Evidence-Based Rationale
The 2024 ESC Guidelines for Atrial Fibrillation provide the most definitive guidance: "Oral anticoagulation is recommended in all patients with AF and hypertrophic cardiomyopathy or cardiac amyloidosis, regardless of CHA2DS2-VA score, to prevent ischaemic stroke and thromboembolism" (Class I, Level B) 1. This recommendation extends beyond atrial fibrillation—cardiac amyloidosis itself creates a prothrombotic state with high risk of left atrial thrombosis even in sinus rhythm 2.
Why Anticoagulation Over Antiplatelets?
The guidelines are unequivocal that antiplatelet therapy is not recommended as an alternative to anticoagulation in patients requiring stroke prevention 1. The 2024 ESC AF Guidelines explicitly state: "Adding antiplatelet treatment to oral anticoagulation is not recommended in AF patients for the goal of preventing ischaemic stroke or thromboembolism" and "Adding antiplatelet treatment to anticoagulation is not recommended in patients with AF to prevent recurrent embolic stroke" 1.
DOAC Selection
Direct oral anticoagulants are recommended in preference to vitamin K antagonists (Class I, Level A) 1. The 2024 guidelines note that DOACs should be preferred over warfarin for stroke prevention except in patients with mechanical heart valves or moderate-to-severe mitral stenosis 1.
The CCS/CHFS statement on cardiac amyloidosis recommends preferring DOACs over warfarin in the absence of contraindications, despite lack of specific evidence in this population 2.
Clinical Algorithm for This Patient
- Confirm the diagnosis: Acute ischemic stroke in a patient with known cardiac amyloidosis
- Assess for atrial fibrillation: If present, this further strengthens the indication for anticoagulation
- Rule out contraindications to anticoagulation: Active bleeding, severe bleeding risk
- Initiate DOAC therapy: Choose apixaban, rivaroxaban, dabigatran, or edoxaban based on renal function and bleeding risk profile
- Do NOT use DAPT: Antiplatelet therapy alone is inadequate for this prothrombotic condition
Important Caveats
Timing After Acute Stroke
While the guidelines don't specify exact timing for anticoagulation initiation after acute stroke in cardiac amyloidosis, general stroke guidelines suggest careful consideration of stroke size and hemorrhagic transformation risk. For large strokes, delaying anticoagulation by several days may be prudent.
Sinus Rhythm Consideration
Even if your patient is in sinus rhythm, the ESC statement advises "to consider [anticoagulation] in selected cases in sinus rhythm" for cardiac amyloidosis 2. The AHA document notes that "decreased A-wave amplitude and left atrial appendage velocities on echocardiography" may warrant empirical anticoagulation even without atrial fibrillation 2.
DAPT Has No Role Here
The extensive evidence supporting short-term DAPT (21-30 days) for minor non-cardioembolic stroke 3, 4 does not apply to your patient. Cardiac amyloidosis creates a cardioembolic risk profile requiring anticoagulation, not antiplatelet therapy. The 2023 World Stroke Organization guidelines clearly state that antiplatelet therapy is for "patients with non-cardioembolic ischemic events who do not require oral anticoagulation" 3—your patient requires anticoagulation.
Bleeding Risk Management
If bleeding risk is prohibitive, left atrial appendage closure may be considered as an alternative 2, though anticoagulation remains the primary recommendation.
The bottom line: Cardiac amyloidosis mandates anticoagulation with a DOAC for stroke prevention, making DAPT an inappropriate choice for secondary prevention in this clinical scenario.